Biodel Company Profile (NASDAQ:ALBO)

About Biodel (NASDAQ:ALBO)

Biodel logoBiodel Inc. is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia. It also develops insulin formulations for Type 1 and Type 2 diabetes patients. Its product pipeline includes RHI-based Ultra-Rapid-Acting Insulin, Analog-based Ultra-Rapid-Acting Insulin, Concentrated Ultra-Rapid-Acting Insulin and Glucagon. The Company's BIOD-531 is a Concentrated Ultra-Rapid-Acting Insulin and its insulin analog-based ultra-rapid-acting insulin product candidates include BIOD-123, BIOD-531, BIOD-238 and BIOD-250. It also conducts pre-clinical testing to develop liquid formulations of glucagon for hypoglycemic rescue and other indications.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ALBO
  • CUSIP: N/A
  • Web:
  • Market Cap: $236.26 million
  • Outstanding Shares: 8,882,000
Average Prices:
  • 50 Day Moving Avg: $22.91
  • 200 Day Moving Avg: $22.28
  • 52 Week Range: $14.00 - $37.69
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.73
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $3.27 million
  • Price / Sales: 72.25
  • Book Value: $8.49 per share
  • Price / Book: 3.13
  • EBITDA: ($18,880,000.00)
  • Current Ratio: 8.64%
  • Quick Ratio: 8.64%
  • Average Volume: 18,616 shs.
  • Beta: 1.43
  • Short Ratio: 1.32

Frequently Asked Questions for Biodel (NASDAQ:ALBO)

What is Biodel's stock symbol?

Biodel trades on the NASDAQ under the ticker symbol "ALBO."

How were Biodel's earnings last quarter?

Biodel Inc. (NASDAQ:ALBO) issued its quarterly earnings data on Monday, August, 21st. The company reported ($0.86) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.84) by $0.02. View Biodel's Earnings History.

Where is Biodel's stock going? Where will Biodel's stock price be in 2017?

5 brokers have issued 1-year target prices for Biodel's shares. Their predictions range from $35.00 to $58.00. On average, they anticipate Biodel's share price to reach $46.50 in the next twelve months. View Analyst Ratings for Biodel.

Who are some of Biodel's key competitors?

How do I buy Biodel stock?

Shares of Biodel can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biodel's stock price today?

One share of Biodel stock can currently be purchased for approximately $26.60.

MarketBeat Community Rating for Biodel (NASDAQ ALBO)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  73 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  166
MarketBeat's community ratings are surveys of what our community members think about Biodel and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Biodel (NASDAQ:ALBO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $46.50 (74.81% upside)
Consensus Price Target History for Biodel (NASDAQ:ALBO)
Price Target History for Biodel (NASDAQ:ALBO)
Analysts' Ratings History for Biodel (NASDAQ:ALBO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/11/2017WedbushReiterated RatingOutperform$58.00LowView Rating Details
8/16/2017Cowen and CompanyInitiated CoverageOutperformHighView Rating Details
7/18/2017Needham & Company LLCInitiated CoverageBuy -> Buy$35.00HighView Rating Details
2/16/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuyN/AView Rating Details
1/25/2017William BlairInitiated CoverageOutperformN/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for Biodel (NASDAQ:ALBO)
Earnings by Quarter for Biodel (NASDAQ:ALBO)
Earnings History by Quarter for Biodel (NASDAQ ALBO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/21/20176/30/2017($0.84)($0.86)ViewN/AView Earnings Details
5/10/2017Q2 2017($1.11)($1.06)ViewN/AView Earnings Details
8/11/2016Q216($0.05)ViewN/AView Earnings Details
5/9/2016Q2($0.04)($0.09)ViewN/AView Earnings Details
2/16/2016Q1($0.08)($0.05)ViewN/AView Earnings Details
12/17/2015Q315($0.11)($0.05)ViewListenView Earnings Details
8/13/2015Q3($0.10)($0.12)ViewListenView Earnings Details
5/6/2015Q215($0.23)($0.27)ViewN/AView Earnings Details
2/12/2015Q115($0.18)($0.20)ViewN/AView Earnings Details
12/17/2014Q414($0.27)($0.16)ViewN/AView Earnings Details
8/11/2014Q2 2014($0.26)($0.15)ViewN/AView Earnings Details
5/13/2014Q114($0.26)($0.29)ViewN/AView Earnings Details
2/6/2014Q4($0.19)($0.20)ViewN/AView Earnings Details
12/18/2013Q4($0.30)($0.04)ViewListenView Earnings Details
8/12/2013Q3 2013($0.37)($0.66)ViewN/AView Earnings Details
5/8/2013Q2 2013($0.43)($0.37)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Biodel (NASDAQ:ALBO)
2017 EPS Consensus Estimate: ($3.37)
2018 EPS Consensus Estimate: ($3.06)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.91)($0.91)($0.91)
Q2 20171($0.87)($0.87)($0.87)
Q3 20172($0.79)($0.76)($0.78)
Q4 20172($0.86)($0.77)($0.82)
Q1 20181($0.76)($0.76)($0.76)
Q2 20181($0.76)($0.76)($0.76)
Q3 20181($0.77)($0.77)($0.77)
Q4 20181($0.77)($0.77)($0.77)
(Data provided by Zacks Investment Research)


Dividend History for Biodel (NASDAQ:ALBO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Biodel (NASDAQ:ALBO)
Insider Ownership Percentage: 22.30%
Institutional Ownership Percentage: 27.36%
Insider Trades by Quarter for Biodel (NASDAQ:ALBO)
Insider Trades by Quarter for Biodel (NASDAQ:ALBO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/20/2013Brian Jg PereiraDirectorSell4,734$2.26$10,698.84View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Biodel (NASDAQ:ALBO)
Latest Headlines for Biodel (NASDAQ:ALBO)
DateHeadline logoAlbireo to Host KOL Event on Progressive Familial Intrahepatic Cholestasis - October 16 at 4:37 PM logoBiodel Inc. (ALBO) Expected to Announce Earnings of -$0.85 Per Share - October 7 at 8:24 PM logoBiodel Inc. (ALBO) Given Average Rating of "Buy" by Brokerages - October 5 at 2:32 AM logoFinal Results of Albireo’s Phase 2 Study of A4250 in Children with Cholestatic Liver Disease to be Presented at The Liver Meeting® 2017 - October 3 at 3:26 PM logoAlbireo to Present at Investor Conferences in September - September 19 at 3:44 PM logo-$0.85 EPS Expected for Biodel Inc. (ALBO) This Quarter - September 19 at 2:18 AM logoAlbireo Pharma (ALBO) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow - September 14 at 4:14 PM logoBiodel Inc. (ALBO) to Post Q3 2017 Earnings of ($0.76) Per Share, Wedbush Forecasts - September 14 at 7:27 AM logoBiodel Inc. (ALBO) to Post FY2020 Earnings of ($3.25) Per Share, Wedbush Forecasts - September 13 at 4:02 PM logoBiodel Inc. (ALBO) Rating Reiterated by Wedbush - September 11 at 9:32 PM logoAlbireo to Present at 19th Annual Rodman & Renshaw Global Investment Conference - September 5 at 5:09 PM logoQ3 2017 Earnings Forecast for Biodel Inc. (ALBO) Issued By William Blair - August 23 at 8:22 AM logoBiodel Inc. (ALBO) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS - August 22 at 10:31 AM logoAlbireo Reports Second Quarter 2017 Financial Results - August 21 at 3:51 PM logoBiodel Inc. (ALBO) Coverage Initiated by Analysts at Cowen and Company - August 20 at 11:58 PM logoBiodel Inc. (ALBO) Given Consensus Recommendation of "Buy" by Analysts - August 16 at 10:54 AM logo Brokerages Anticipate Biodel Inc. (ALBO) Will Post Earnings of -$0.83 Per Share - August 13 at 4:16 AM logoAlbireo to Present at Wedbush PacGrow Healthcare Conference - August 8 at 3:38 PM logoWhat's in the Cards for Humana (HUM) this Earnings Season? - July 31 at 3:50 PM logoWhat's in the Cards for Merrimack (MACK) in Q2 Earnings? - July 28 at 4:19 PM logoEndo International PLC (ENDP) and Biodel (NASDAQ:ALBO) Financial Review - July 16 at 2:11 PM logoComparing Biodel (NASDAQ:ALBO) & Endo International PLC (ENDP) - July 7 at 8:28 PM logoBiodel (ALBO) & Endo International PLC (ENDP) Financial Comparison - July 6 at 12:32 AM logoResearch Analysts Set Expectations for Biodel Inc.'s FY2017 Earnings (NASDAQ:ALBO) - July 3 at 8:34 AM logoBiodel Inc. (NASDAQ:ALBO) Receives New Coverage from Analysts at Wedbush - July 1 at 12:02 PM logoCompany Spotlight: Albireo Pharma - - Nasdaq - June 2 at 4:33 PM logoCompany Spotlight: Albireo Pharma - June 2 at 1:46 AM logoALBO Spikes, GLYC Abuzz, FDA Approves 1st Generic Strattera For ADHD - Nasdaq - May 31 at 3:26 PM logoAlbireo Announces Closing of $51.9 Million Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares - May 31 at 11:06 AM logoAlbireo Announces Closing of $51.9 Million Public Offering Including Exercise of Underwriters' Option to Purchase ... - GlobeNewswire (press release) - May 30 at 8:36 PM logoBUZZ-U.S. STOCKS ON THE MOVE-Micron Technology, Atwood Oceanics, Xactly, Protagonist Therapeutics ... - Nasdaq - May 30 at 3:35 PM logoAlbireo Pharma (ALBO) Prices 2.2M Common Stock Offering at $20.50/Share - - May 25 at 1:36 AM logoAlbireo Pharma (ALBO) Prices 2.2M Common Stock Offering at $20.50/Share - May 24 at 3:26 PM logoAlbireo Pharma (ALBO) Commences Offering of Common Stock - - May 24 at 7:23 AM logoAlbireo Pharma (ALBO) Reports Two New U.S. Patents Allowed for A4250 with Term into 2031 - May 16 at 8:33 PM logoAlbireo Pharma (ALBO) Reports Two New U.S. Patents Allowed for ... - - May 16 at 3:31 PM logoAlbireo Reports First Quarter 2017 Financial Results - GlobeNewswire (press release) - May 11 at 1:39 AM logoAlbireo Pharma (ALBO) to Present Pediatric Data for A4250 at The International Liver Congress - - April 24 at 3:28 PM logoPromising Pediatric Data for Albireo's A4250 to be Presented at The ... - GlobeNewswire (press release) - April 22 at 3:23 PM logoAlbireo Pharma (ALBO) Presents At 16th Annual Needham Healthcare Conference - Slideshow - April 7 at 8:28 PM logoAlbireo Pharma (ALBO) Says A4250 Data Selected for Late Breaker Presentation as ILC - - April 7 at 7:49 AM logoEASL Selects Albireo's A4250 Data for Late Breaker Presentation - April 5 at 8:32 AM logoAlbireo Reports 2016 Financial Results - March 14 at 3:23 PM logoALBIREO PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi - March 14 at 3:23 PM logo7:38 am Albireo Pharma reports FY16 results; initiation of A4250 Phase 3 trial planned for 2H 2017 - March 14 at 3:23 PM logoAlbireo Reports 2016 Financial Results - GlobeNewswire (press release) - March 14 at 8:09 AM logoALBIREO PHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial O - February 10 at 8:55 PM logoALBIREO PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers - January 27 at 8:40 PM logoALBIREO PHARMA, INC. Files SEC form 10-K, Annual Report - December 22 at 8:27 PM logoALBIREO PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits - December 21 at 9:30 PM



Biodel (ALBO) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.